Evelo Biosciences (EVLO) Competitors $0.0015 0.00 (0.00%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesOwnershipSEC FilingsTrends EVLO vs. CALA, VAXX, SCPS, AMPE, ARDS, CMRA, GNCA, GNCAQ, STAB, and EFTRShould you be buying Evelo Biosciences stock or one of its competitors? The main competitors of Evelo Biosciences include Calithera Biosciences (CALA), Vaxxinity (VAXX), Scopus BioPharma (SCPS), Ampio Pharmaceuticals (AMPE), Aridis Pharmaceuticals (ARDS), Comera Life Sciences (CMRA), Genocea Biosciences (GNCA), Genocea Biosciences (GNCAQ), Statera Biopharma (STAB), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry. Evelo Biosciences vs. Calithera Biosciences Vaxxinity Scopus BioPharma Ampio Pharmaceuticals Aridis Pharmaceuticals Comera Life Sciences Genocea Biosciences Genocea Biosciences Statera Biopharma eFFECTOR Therapeutics Calithera Biosciences (NASDAQ:CALA) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations. Which has stronger earnings & valuation, CALA or EVLO? Calithera Biosciences has higher revenue and earnings than Evelo Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalithera Biosciences$9.75M0.00-$39.65MN/AN/AEvelo BiosciencesN/AN/A-$114.53M-$13.290.00 Which has more risk and volatility, CALA or EVLO? Calithera Biosciences has a beta of -1.09, suggesting that its stock price is 209% less volatile than the S&P 500. Comparatively, Evelo Biosciences has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Is CALA or EVLO more profitable? Company Net Margins Return on Equity Return on Assets Calithera BiosciencesN/A N/A N/A Evelo Biosciences N/A N/A N/A Does the MarketBeat Community prefer CALA or EVLO? Calithera Biosciences received 171 more outperform votes than Evelo Biosciences when rated by MarketBeat users. However, 60.50% of users gave Evelo Biosciences an outperform vote while only 57.12% of users gave Calithera Biosciences an outperform vote. CompanyUnderperformOutperformCalithera BiosciencesOutperform Votes34157.12% Underperform Votes25642.88% Evelo BiosciencesOutperform Votes17060.50% Underperform Votes11139.50% Does the media favor CALA or EVLO? In the previous week, Calithera Biosciences had 2 more articles in the media than Evelo Biosciences. MarketBeat recorded 3 mentions for Calithera Biosciences and 1 mentions for Evelo Biosciences. Calithera Biosciences' average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Calithera Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evelo Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in CALA or EVLO? 0.3% of Evelo Biosciences shares are held by institutional investors. 6.6% of Calithera Biosciences shares are held by company insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryCalithera Biosciences beats Evelo Biosciences on 5 of the 8 factors compared between the two stocks. Ad DTII've got news for you… Today, I’m doing something I thought I’d never do… Especially since I’m not normally a “swing for the fences” type of trader. But I’ve been quietly testing a new type of trade for a while now… And the returns are too good not to share with you. Take a look… I can’t guarantee results or against losses, but if you want to discover how I’ll target the triple return before the end of the weekwatch this FREE briefing with me and expert trader Graham Lindman Get Evelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVLO vs. The Competition Export to ExcelMetricEvelo BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$28,000.00$6.56B$5.22B$8.83BDividend YieldN/A8.13%5.53%4.07%P/E Ratio0.0010.1392.5417.54Price / SalesN/A359.911,233.8694.97Price / CashN/A53.8341.4336.95Price / Book0.0010.597.236.54Net Income-$114.53M$153.02M$119.89M$226.07M7 Day PerformanceN/A3.96%2.14%3.77%1 Month PerformanceN/A-6.72%-2.23%4.46%1 Year PerformanceN/A30.92%32.63%27.57% Evelo Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVLOEvelo BiosciencesN/A$0.00flatN/A-99.8%$28,000.00N/A0.00120Gap UpCALACalithera BiosciencesN/A$0.01flatN/A-75.3%$36,000.00$9.75M0.0060Analyst ForecastNews CoverageVAXXVaxxinityN/A$0.00flatN/A-100.0%$25,000.00$70,000.000.0090SCPSScopus BioPharmaN/A$0.00flatN/A-99.4%$13,000.00N/A0.009AMPEAmpio PharmaceuticalsN/A$0.01flatN/A-96.4%$11,000.00N/A-0.0120Analyst ForecastNews CoverageGap UpARDSAridis PharmaceuticalsN/AN/AN/AN/A$10,000.00$3.09M0.0030CMRAComera Life SciencesN/A$0.00flatN/AN/A$9,000.00$1.00M0.002GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070GNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.64M0.0070STABStatera BiopharmaN/AN/AN/AN/A$5,000.00$1.49M0.0020High Trading VolumeEFTReFFECTOR Therapeutics1.151 of 5 stars$0.00flat$24.00+11,999,900.0%-100.0%$1,000.00$3.55M0.0010 Related Companies and Tools Related Companies CALA Alternatives VAXX Alternatives SCPS Alternatives AMPE Alternatives ARDS Alternatives CMRA Alternatives GNCA Alternatives GNCAQ Alternatives STAB Alternatives EFTR Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EVLO) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredA “Thank You Gift” From Pres. Trump - GeniusTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | Sponsored#1 Crypto of 2024Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
